Cargando…
702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial
BACKGROUND: Live biotherapeutic products (LBPs) are adjunctive therapies to prevent recurrence of Clostridioides difficile infection (CDI). In this post hoc subgroup analysis, the durability of fecal microbiota, live-jslm (REBYOTA™; abbreviated here as RBL, previously known as RBX2660), the first mi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678640/ http://dx.doi.org/10.1093/ofid/ofad500.764 |